Chronic Lymphocytic Leukemia | Residual Tumor | partial response | Partial response Lymph nodes | In complete remission | MRD Following Neoadjuvant Therapy | Pentostatin | Cyclophosphamide | rituximab
Item
cll patients with evidence of residual disease, who have achieved pr, npr or cr with detectable mrd following upfront therapy consisting of pentostatin, cyclophosphamide and rituximab.
boolean
C0023434 (UMLS CUI [1])
C0543478 (UMLS CUI [2])
C1521726 (UMLS CUI [3])
C1521726 (UMLS CUI [4,1])
C0024204 (UMLS CUI [4,2])
C0677874 (UMLS CUI [5])
C0242596 (UMLS CUI [6,1])
C0332282 (UMLS CUI [6,2])
C0600558 (UMLS CUI [6,3])
C0030896 (UMLS CUI [7])
C0010583 (UMLS CUI [8])
C0393022 (UMLS CUI [9])
MRD Flow Cytometry | MRD Polymerase Chain Reaction
Item
the presence of mrd will be assessed by the flow cytometry and polymerasechain reaction at the mskcc diagnostic molecular pathology laboratory.
boolean
C0242596 (UMLS CUI [1,1])
C0016263 (UMLS CUI [1,2])
C0242596 (UMLS CUI [2,1])
C0032520 (UMLS CUI [2,2])
Age
Item
age ≥ 18 years of age.
boolean
C0001779 (UMLS CUI [1])
Creatinine measurement, serum | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Prothrombin time assay | Activated Partial Thromboplastin Time measurement | Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement | Support transfusion therapy
Item
creatinine ≤2.0 mg/100 ml, bilirubin ≤2.0 mg/100 ml, ast and alt ≤3.0x normal, pt and ptt ≤2x normal outside the setting of stable chronic anticoagulation therapy, absolute neutrophil count ≥500/mm3, platelets ≥50,000/mm3, hemoglobin ≥8.0g/dl with transfusion support.
boolean
C0201976 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C0033707 (UMLS CUI [5])
C0030605 (UMLS CUI [6])
C0948762 (UMLS CUI [7])
C0032181 (UMLS CUI [8])
C0518015 (UMLS CUI [9])
C0436311 (UMLS CUI [10])
Pulmonary function | Oxygen saturation measurement on room air Pulse Oximetry
Item
adequate pulmonary function as assessed by ≥92% oxygen saturation on room air by pulse oximetry.
boolean
C0231921 (UMLS CUI [1])
C0523807 (UMLS CUI [2,1])
C2709070 (UMLS CUI [2,2])
C0034108 (UMLS CUI [2,3])
Karnofsky Performance Status
Item
karnofsky performance status <70.
boolean
C0206065 (UMLS CUI [1])
Pregnancy | Breast Feeding | Females & males of reproductive potential Contraceptive methods
Item
pregnant or lactating women. women and men of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finished.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C4034483 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
Decreased cardiac function | Left ventricular ejection fraction Echocardiography | Left ventricular ejection fraction MUGA scan
Item
impaired cardiac function (lvef <40%) as assessed by echo or muga scan.
boolean
C0232166 (UMLS CUI [1])
C0428772 (UMLS CUI [2,1])
C0013516 (UMLS CUI [2,2])
C0428772 (UMLS CUI [3,1])
C0521317 (UMLS CUI [3,2])
Allogeneic bone marrow transplantation | Allogeneic hematopoietic stem cell transplant
Item
patients previously treated with allogeneic bone marrow or stem cell transplantation are ineligible.
boolean
C0149615 (UMLS CUI [1])
C4255274 (UMLS CUI [2])
Patients Appropriate Allogeneic bone marrow transplantation | Patients Appropriate Allogeneic hematopoietic stem cell transplant
Item
patients who are immediate candidates for allogeneic bone marrow or stem cell transplantation. patients who refuse this option remain eligible and need to be documented as such in patient medical record.
boolean
C0030705 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C0149615 (UMLS CUI [1,3])
C0030705 (UMLS CUI [2,1])
C1548787 (UMLS CUI [2,2])
C4255274 (UMLS CUI [2,3])
Chronic Lymphocytic Leukemia with Richter's syndrome
Item
cll patients with transformed disease (richter's transformation) are ineligible for enrollment on this study.
boolean
C0023434 (UMLS CUI [1,1])
C0332287 (UMLS CUI [1,2])
C0349631 (UMLS CUI [1,3])
Condition cardiac
Item
patients with following cardiac conditions will be excluded:
boolean
C0348080 (UMLS CUI [1,1])
C0018787 (UMLS CUI [1,2])
Congestive heart failure New York Heart Association Classification
Item
new york heart association (nyha) stage iii or iv congestive heart failure
boolean
C0018802 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
Myocardial Infarction
Item
myocardial infarction ≤6 months prior to enrollment
boolean
C0027051 (UMLS CUI [1])
Ventricular arrhythmia | Syncope Unexplained | Exception Vasovagal syncope | Exception Due to Dehydration
Item
history of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration
boolean
C0085612 (UMLS CUI [1])
C0039070 (UMLS CUI [2,1])
C4288071 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0042420 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0678226 (UMLS CUI [4,2])
C0011175 (UMLS CUI [4,3])
Non-ischemic cardiomyopathy Severe | Cardiac ejection fraction
Item
history of severe non-ischemic cardiomyopathy with ef ≤20%
boolean
C0877438 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0232174 (UMLS CUI [2])
HIV Infection | Hepatitis B | Hepatitis C
Item
patients with hiv and active hepatitis b or hepatitis c infection are ineligible.
boolean
C0019693 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
Cancer Other Treatment required for | Exception Patient observation | Exception Squamous cell carcinoma of skin | Exception Basal cell carcinoma
Item
patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation, with the exception of squamous and basal cell carcinoma of skin.
boolean
C1707251 (UMLS CUI [1,1])
C0332121 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0700325 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0007117 (UMLS CUI [4,2])
Step Registration | Therapy
Item
step 2 registration (treatment):
boolean
C1261552 (UMLS CUI [1,1])
C1514821 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2])
Criteria Fulfill | T-Lymphocyte Infusion
Item
the following additional criteria must be met in order for a patient to be eligible to receive the modified t cell infusion. these labs are to be obtained within 2 weeks of t cell infusion.
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
C0039194 (UMLS CUI [2,1])
C0574032 (UMLS CUI [2,2])
Creatinine measurement, serum | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Prothrombin time assay | Activated Partial Thromboplastin Time measurement | Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement | Support transfusion therapy
Item
creatinine ≤2.0 mg/100 ml, bilirubin ≤2.0 mg/100 ml, ast and alt ≤3.0x normal, pt and ptt ≤2x normal outside the setting of stable chronic anticoagulation therapy, absolute neutrophil count ≥500/mm3, platelets ≥50,000/mm3, hemoglobin ≥8.0g/dl with transfusion support.
boolean
C0201976 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C0033707 (UMLS CUI [5])
C0030605 (UMLS CUI [6])
C0948762 (UMLS CUI [7])
C0032181 (UMLS CUI [8])
C0518015 (UMLS CUI [9])
C0436311 (UMLS CUI [10])